个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhang Juan[1] * ; Kan Jing[1] * ; Wei Yongyue[2] * ; Zhang Caojin[3] * ; Yang Zhenwen[4] ; Gu Heping[5] ; Fan Fenling[6] ; Gu Hong[7] ; Wang Qiguang[8] ; Xie Dujiang[1] ; Zhang Gangcheng[9] ; Guo Xiaomei[10] ; Yin Yuehui[11] ; Jin Bowen[12] ; Zhou Hongmei[12] ; Yang Ziyang[3] ; Wang Zhouming[4] ; Xin Yu[5] ; Zhang Chen[7] ; Meng Lili[8] ; Wang Xiaoyu[6] ; Zhao Chunxia[10] ; Zhang Hang[1] ; Yan Xiaoyan[13] ; Chen Feng[2] ; Yao Cheng[13] ; Benza Raymond L[14] ; Stone Gregg W[15] ; Chen Shao-Liang[1,*1] ;
单位： [1]Division of Cardiology, Nanjing First Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. [2]School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China. [3]Division of Cardiology, Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China. [4]Division of Pulmonary vascular disease, General Hospital of Tianjin Medical University, Tianjin, China. [5]Division of Cardiology, First Hospital of Zhengzhou University, Zhengzhou, Henan, China. [6]Division of Pulmonary vascular disease, First Affiliated Hospital of Xi'An Jiaotong University, Xi'An, Shanxi, China. [7]Division of congenital heart disease, Beijing Anzhen Hospital of Capital Medical University, Beijing, China. [8]Division of Pulmonary vascular disease, General Hospital of Northen Theater of Command, Shenyang, Liaoning, China. [9]Division of Pulmonary vascular disease, Zhongnan Hospital of Wuhan University,Wuhan, Hubei, China. [10]Division of Cardiology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China. [11]Division of Cardiology, Second Hospital of Chongqing Medical University, Chongqing, China. [12]Division of Pulmonary vascular disease, Wuhan Asia Heart hospital, Wuhan, Hubei, China. [13]Peking University Clinical Research Institute, Beijing, China. [14]Division of Cardiovascular Medicine, The Ohio State University, Cleveland, Ohio, US. [15]The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
出处：
DOI： 10.1016/j.healun.2023.03.015
ISSN：

关键词： riskstratification pulmonaryarterialhypertension pulmonaryarterydenervation

摘要：
The differential treatment effect of pulmonary artery denervation (PADN) in pulmonary arterial hypertension (PAH) patients with different risk burdens remains unclear. This study aimed to determine the effectiveness of PADN in low vs intermediate-high-risk PAH patients.In total, 128 patients with treatment naive PAH included in the PADN-CFDA trial were categorized into low-risk and intermediate-high-risk patients. The primary endpoint was the between-group difference in the change in 6-min walk distance (6 MWD) from baseline to 6 months.In the intermediate-high-risk group, those treated with PADN and PDE-5i had a greater improvement in 6 MWD from baseline to 6 months as compared to those treated with sham plus PDE-5i. From baseline to 6 months, pulmonary vascular resistance (PVR) was reduced by -6.1 ± 0.6 and -2.0 ± 0.7 Wood units following PADN plus PDE-5i and sham plus PDE-5i, respectively, along with the significant reduction of NT-proBNP in the intermediate-high-risk group. However, there were no significant differences in 6 MWD, PVR, and NT-proBNP between the PADN plus PDE-5i and sham plus PDE-5i groups among low-risk patients. Moreover, the right ventricular function was equally improved by PADN treatment across the low-, intermediate-, and high-risk groups. Clinical worsening was less with PADN plus PDE-5i treatment during the 6-month follow-up.In patients with pulmonary arterial hypertension, pulmonary artery denervation plus PDE-5i improved exercise capacity, NT-proBNP, hemodynamic, and clinical outcomes during the 6-month follow-up among intermediate-high risk patients.Copyright © 2023 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

基金：
ThistrialwasgrantedbytheNationalScientificFoundationofChina(grantnumbers:NSFC91639303,NSFC81770441,andNSFC82121001).NanjingFirstHospitalfundedthistrial,andPulnovoprovidedallPADNcathetersthroughoutthestudyperiod
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 呼吸系统 1 区 外科 1 区 移植 2 区 心脏和心血管系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 外科 1 区 移植 2 区 心脏和心血管系统 2 区 呼吸系统
JCR分区：
出版当年[2021]版：
Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Q1 RESPIRATORY SYSTEM Q1 SURGERY Q1 TRANSPLANTATION
最新[2023]版：
Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Q1 RESPIRATORY SYSTEM Q1 SURGERY Q1 TRANSPLANTATION

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Division of Cardiology, Nanjing First Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
共同第一作者：
通讯作者：
通讯机构： [1]Division of Cardiology, Nanjing First Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. [*1]Division of Cardiology, Nanjing First Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
推荐引用方式(GB/T 7714)：
Zhang Juan,Kan Jing,Wei Yongyue,et al.Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial[J].JOURNAL OF HEART AND LUNG TRANSPLANTATION.2023,42(8):1140-1151.doi:10.1016/j.healun.2023.03.015.
APA：
Zhang Juan,Kan Jing,Wei Yongyue,Zhang Caojin,Yang Zhenwen...&Chen Shao-Liang.(2023).Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial.JOURNAL OF HEART AND LUNG TRANSPLANTATION,42,(8)
MLA：
Zhang Juan,et al."Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial".JOURNAL OF HEART AND LUNG TRANSPLANTATION 42..8(2023):1140-1151

相关文献

[1]便携式一体化腹膜外腔扩张器 [2]一种用于桡动脉远端穿刺的压迫止血器 [3]一种用于头颈部肿瘤患者用口腔撑开器 [4]一种可检测呼气末二氧化碳的纤维支气管镜 [5]一种肠道菌群超级供体画像信息检测生成方法 [6]结合小鼠PD-L1和TGF-β的双特异性抗体及其制备方法与应用 [7]一种蓝牙听诊器 [8]一种防摔拐杖 [9]一种单向导湿的尿路造口袋 [10]一种肿瘤胃肠营养胃管连接装置

资源点击量：589 今日访问量：0 总访问量：441 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）